Related Experiment Video
Updated: Nov 9, 2025

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones
Published on: July 25, 2019
Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer
Su H Park1, Ka-Wing Fong1, Jung Kim1,2
1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract:
Forkhead box protein A1 (FOXA1) is essential for androgen-dependent prostate cancer (PCa) growth. However, how FOXA1 levels are regulated remains elusive and its therapeutic targeting proven challenging. Here, we report FOXA1 as a nonhistone substrate of enhancer of zeste homolog 2 (EZH2), which methylates FOXA1 at lysine-295. This methylation is recognized by WD40 repeat protein BUB3, which subsequently recruits ubiquitin-specific protease 7 (USP7) to remove ubiquitination and enhance FOXA1 protein stability. They functionally converge in regulating cell cycle genes and promoting PCa growth. FOXA1 is a major therapeutic target of the inhibitors of EZH2 methyltransferase activities in PCa. FOXA1-driven PCa growth can be effectively mitigated by EZH2 enzymatic inhibitors, either alone or in combination with USP7 inhibitors. Together, our study reports EZH2-catalyzed methylation as a key mechanism to FOXA1 protein stability, which may be leveraged to enhance therapeutic targeting of PCa using enzymatic EZH2 inhibitors.
Insights
Researchers discovered enhancer of zeste homolog 2 (EZH2) methylates Forkhead box protein A1 (FOXA1), stabilizing it and promoting prostate cancer (PCa) growth. This finding offers new therapeutic strategies targeting EZH2 and USP7 for PCa treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Forkhead box protein A1 (FOXA1) is crucial for prostate cancer (PCa) progression.
- Mechanisms regulating FOXA1 protein levels and its therapeutic targeting in PCa are not fully understood.
Purpose of the Study:
- To elucidate the regulatory mechanisms governing FOXA1 protein stability.
- To investigate the role of FOXA1 regulation in prostate cancer growth.
- To explore potential therapeutic strategies targeting FOXA1 stability in PCa.
Main Methods:
- Identified FOXA1 as a nonhistone substrate of enhancer of zeste homolog 2 (EZH2).
- Investigated the role of EZH2-mediated methylation at lysine-295 of FOXA1.
- Examined the interaction of methylated FOXA1 with WD40 repeat protein BUB3 and ubiquitin-specific protease 7 (USP7).
Main Results:
- EZH2 methylates FOXA1 at lysine-295, enhancing its protein stability via BUB3 and USP7.
- This regulatory axis (EZH2-FOXA1-BUB3-USP7) controls cell cycle genes and promotes PCa growth.
- Inhibitors targeting EZH2 methyltransferase activity mitigate FOXA1-driven PCa growth.
Conclusions:
- EZH2-catalyzed methylation is a key mechanism for FOXA1 protein stabilization in prostate cancer.
- Targeting EZH2 enzymatic activity, alone or with USP7 inhibitors, shows therapeutic potential for PCa.
- Understanding this regulatory pathway provides novel avenues for PCa treatment strategies.
Related Concept Videos
Regulation of Expression at Multiple Steps
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Master Transcription Regulators

